240 related articles for article (PubMed ID: 33784425)
1. HMGB1: An overview of its roles in the pathogenesis of liver disease.
Ni YA; Chen H; Nie H; Zheng B; Gong Q
J Leukoc Biol; 2021 Nov; 110(5):987-998. PubMed ID: 33784425
[TBL] [Abstract][Full Text] [Related]
2. Role of High-Mobility Group Box-1 in Liver Pathogenesis.
Khambu B; Yan S; Huda N; Yin XM
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731454
[TBL] [Abstract][Full Text] [Related]
3. High-Mobility Group Box-1 and Liver Disease.
Gaskell H; Ge X; Nieto N
Hepatol Commun; 2018 Sep; 2(9):1005-1020. PubMed ID: 30202816
[TBL] [Abstract][Full Text] [Related]
4. Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling.
Paudel YN; Angelopoulou E; Piperi C; Balasubramaniam VRMT; Othman I; Shaikh MF
Eur J Pharmacol; 2019 Sep; 858():172487. PubMed ID: 31229535
[TBL] [Abstract][Full Text] [Related]
5. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.
Musumeci D; Roviello GN; Montesarchio D
Pharmacol Ther; 2014 Mar; 141(3):347-57. PubMed ID: 24220159
[TBL] [Abstract][Full Text] [Related]
6. The myocardial infarct-exacerbating effect of cell-free DNA is mediated by the high-mobility group box 1-receptor for advanced glycation end products-Toll-like receptor 9 pathway.
Tian Y; Charles EJ; Yan Z; Wu D; French BA; Kron IL; Yang Z
J Thorac Cardiovasc Surg; 2019 Jun; 157(6):2256-2269.e3. PubMed ID: 30401529
[TBL] [Abstract][Full Text] [Related]
7. High-mobility group protein box-1 and its relevance to cerebral ischemia.
Yang QW; Wang JZ; Li JC; Zhou Y; Zhong Q; Lu FL; Xiang J
J Cereb Blood Flow Metab; 2010 Feb; 30(2):243-54. PubMed ID: 19794402
[TBL] [Abstract][Full Text] [Related]
8. The Immune Tolerance Role of the HMGB1-RAGE Axis.
Watanabe H; Son M
Cells; 2021 Mar; 10(3):. PubMed ID: 33807604
[TBL] [Abstract][Full Text] [Related]
9. High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice.
Ge X; Arriazu E; Magdaleno F; Antoine DJ; Dela Cruz R; Theise N; Nieto N
Hepatology; 2018 Dec; 68(6):2380-2404. PubMed ID: 29774570
[TBL] [Abstract][Full Text] [Related]
10. Extracellular high-mobility group box 1 protein (HMGB1) as a mediator of persistent pain.
Agalave NM; Svensson CI
Mol Med; 2015 Feb; 20(1):569-78. PubMed ID: 25222915
[TBL] [Abstract][Full Text] [Related]
11. Review: Therapeutic Targeting of HMGB1 in Stroke.
Tian X; Liu C; Shu Z; Chen G
Curr Drug Deliv; 2017 Sep; 14(6):785-790. PubMed ID: 27501713
[TBL] [Abstract][Full Text] [Related]
12. High-mobility group box-1 in ischemia-reperfusion injury of the heart.
Andrassy M; Volz HC; Igwe JC; Funke B; Eichberger SN; Kaya Z; Buss S; Autschbach F; Pleger ST; Lukic IK; Bea F; Hardt SE; Humpert PM; Bianchi ME; Mairbäurl H; Nawroth PP; Remppis A; Katus HA; Bierhaus A
Circulation; 2008 Jun; 117(25):3216-26. PubMed ID: 18574060
[TBL] [Abstract][Full Text] [Related]
13. Expatiating the molecular approaches of HMGB1 in diabetes mellitus: Highlighting signalling pathways via RAGE and TLRs.
Behl T; Sharma E; Sehgal A; Kaur I; Kumar A; Arora R; Pal G; Kakkar M; Kumar R; Bungau S
Mol Biol Rep; 2021 Feb; 48(2):1869-1881. PubMed ID: 33479829
[TBL] [Abstract][Full Text] [Related]
14. High-mobility group box-1 in sterile inflammation.
Tsung A; Tohme S; Billiar TR
J Intern Med; 2014 Nov; 276(5):425-43. PubMed ID: 24935761
[TBL] [Abstract][Full Text] [Related]
15. RAGE and TLRs: relatives, friends or neighbours?
Ibrahim ZA; Armour CL; Phipps S; Sukkar MB
Mol Immunol; 2013 Dec; 56(4):739-44. PubMed ID: 23954397
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling.
Mcdonald KA; Huang H; Tohme S; Loughran P; Ferrero K; Billiar T; Tsung A
Mol Med; 2015 Mar; 20(1):639-48. PubMed ID: 25375408
[TBL] [Abstract][Full Text] [Related]
17. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease.
Zhang C; Chen F; Feng L; Shan Q; Zheng GH; Wang YJ; Lu J; Fan SH; Sun CH; Wu DM; Li MQ; Hu B; Wang QQ; Zhang ZF; Zheng YL
Mol Med; 2019 Jun; 25(1):29. PubMed ID: 31215394
[TBL] [Abstract][Full Text] [Related]
18. HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease.
Chandrashekaran V; Seth RK; Dattaroy D; Alhasson F; Ziolenka J; Carson J; Berger FG; Kalyanaraman B; Diehl AM; Chatterjee S
Redox Biol; 2017 Oct; 13():8-19. PubMed ID: 28551086
[TBL] [Abstract][Full Text] [Related]
19. High-mobility group box 1 inhibits gastric ulcer healing through Toll-like receptor 4 and receptor for advanced glycation end products.
Nadatani Y; Watanabe T; Tanigawa T; Ohkawa F; Takeda S; Higashimori A; Sogawa M; Yamagami H; Shiba M; Watanabe K; Tominaga K; Fujiwara Y; Takeuchi K; Arakawa T
PLoS One; 2013; 8(11):e80130. PubMed ID: 24244627
[TBL] [Abstract][Full Text] [Related]
20. High-mobility group box 1 promotes extracellular matrix synthesis and wound repair in human bronchial epithelial cells.
Ojo OO; Ryu MH; Jha A; Unruh H; Halayko AJ
Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(11):L1354-66. PubMed ID: 26432865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
